Since January 1, 2014, there have been 332 IPOs on either the NYSE or the Nasdaq. Earlier today we ran a screen on Bloomberg that ranked these IPOs by their returns since their IPO. Specifically, we measured the returns from the opening price on the first day of trading to today's close. Here are the top 10 stocks per this screen:
1. Atara Biotherapeutics (ATRA), up 281% since Oct 15, 2014 IPO. This company develops treatments for cancer, kidney disease and other illnesses.
2. Eagle Pharmaceuticals (EGRX) up 276% since Feb 12, 2014 IPO. The company develops a variety of specialty drugs via injectables.
3. Alder Biopharmaceuticals (ALDR) up 234% since May 8, 2014 IPO. Develops antibody therapeutics for cancer, pain, cardiovascular and autoimmune and inflammatory diseases.
4. Adeptus Health (ADPT) up 157% since June 25, 2014 IPO. Manages an independent network of free-standing emergency rooms in Texas and Colorado.
5. Inogen (INGN) up 130% since Feb 14, 2014. Sells oxygen and supplies for pulmonary disease patients.
6. Nevro Corp (NVRO) up 128% since Nov 5, 2014. Develops spinal cord therapy products to relieve pain.
7. Diplomat Pharmacueticals (DPLO) up 125% since Oct 9, 2014 IPO. Develops pharmaceuticals for complex diseases.
8. Kite Pharmaceuticals (KITE) up 119% since June 20, 2014 IPO. Develops cancer and immunotherapy products.
9. Paycom Software (PAYC) up 114% since April 14, 2014 IPO. Markets cloud-based software for the employment life-cycle.
10. 2U Inc (TWOU) up 113% since March 28, 2014 IPO. Provides a variety of online education courses.
It is interesting to note that the top 8 companies are all in the Healthcare sector. This reflects the fact that the overall IPO market of the last two years in the US has been dominated by healthcare companies, especially in the biotechnology industry. Additionally, in the first quarter of 2015, the healthcare sector within the S&P 500 Index reported the largest earnings increase year-over-year, at 22%, per FactSet. There is no doubt that we are in the midst of a healthcare revolution.
No comments:
Post a Comment